Brecher 1997.

Methods	Randomised, parallel group, multicentre trial (North America). Analysis stated as by ITT. Withdrawals: stated.
Participants	Baseline characteristics: 106 male, 17 female, all participants had stage III disease (Regimen A: 65; Regimen B: 58). Mean age: 8.6 years range 2.3 to 20.3 years. Tumour staging: Murphy classification. Diagnosis: histo‐cytologic diagnosis of SNCCL. Entry criteria: newly‐diagnosed stage III SNCCL, pathology confirmed. Exclusion criteria: not stated.
Interventions	Regimen A: (COMP given for induction, consolidation with the first three dugs; maintenance with O and MTX and nervous‐system prophylaxis, all given at prespecified intervals) versus Regimen B:(duration of treatment being determined by clinical response). Treatment duration: 9 months. Follow‐up: 3 to 8 years.
Outcomes	Overall survival (complete response). Event‐free survival. Remission rate. Relapse rate.
Notes	Full text publication. Study type: remission induction.
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Not described.
Allocation concealment (selection bias)	Unclear risk	Not described.
Blinding (performance bias and detection bias) All outcomes	Unclear risk	Not described.
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	It was reported that one participant in regimen A was "inevaluable for response".